Annovis Bio - Rasio total nilai perusahaan marang pendapatan ANVS

Annovis Bio, Inc. (ANVS) focuses on the collaborative development of drugs for Parkinson's and Alzheimer's diseases in partnership with medical centers. A flexible raw material supplier network ensures margin stability, while current expenses for final trials are covered by existing reserves. The EV/Sales trajectory reflects institutional capital reaction, with the current metric standing at 0.00.
ANVS (Annovis Bio, Inc.): rincian analitis lan laporan miturut indikator

This indicator compares the total enterprise value, adjusted for net debt, against the volume of generated revenue to determine the market revaluation of assets. The EV/Sales ratio trend reflects the capitalization efficiency of investments in screening robotics and clinical data processing automation, allowing for an assessment of the market's willingness to award a premium to Annovis Bio, Inc. (ANVS) for accelerating drug time-to-market.